Effect of donor

Cirrhosis Fatty liver HSD17B13 Liver transplant PNPLA3 Post-transplant survival

Journal

EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 30 08 2023
revised: 15 11 2023
accepted: 17 11 2023
medline: 4 1 2024
pubmed: 4 1 2024
entrez: 3 1 2024
Statut: epublish

Résumé

Several genetic variants are associated with chronic liver disease. The role of these variants in outcomes after liver transplantation (LT) is uncertain. The aim of this study was to determine if donor genotype at risk-associated variants in In this retrospective cohort study, data on 2346 adults who underwent first-time LT between January 1, 1999 and June 30, 2020 and who had donor DNA samples available at five large Transplant Immunology Laboratories in Texas, USA, were obtained from the United Network for Organ Sharing (UNOS). Duplicates, patients with insufficient donor DNA for genotyping, those who were <18 years of age at the time of transplant, had had a previous transplant or had missing genotype data were excluded. The primary outcomes were patient and graft survival after LT. The association between donor genotype and post-LT survival was examined using Kaplan-Meier method and multivariable-adjusted Cox proportional hazards models. Median age of LT recipients was 57 [interquartile range (IQR), 50-62] years; 837 (35.7%) were women; 1362 (58.1%) White, 713 (30.4%) Hispanic, 182 (7.8%) Black/African-American. Median follow-up time was 3.95 years. Post-LT survival was not affected by donor Donor The National Institutes of Health and American Society of Transplant Surgeons Collaborative Scientist Grant.

Sections du résumé

Background UNASSIGNED
Several genetic variants are associated with chronic liver disease. The role of these variants in outcomes after liver transplantation (LT) is uncertain. The aim of this study was to determine if donor genotype at risk-associated variants in
Methods UNASSIGNED
In this retrospective cohort study, data on 2346 adults who underwent first-time LT between January 1, 1999 and June 30, 2020 and who had donor DNA samples available at five large Transplant Immunology Laboratories in Texas, USA, were obtained from the United Network for Organ Sharing (UNOS). Duplicates, patients with insufficient donor DNA for genotyping, those who were <18 years of age at the time of transplant, had had a previous transplant or had missing genotype data were excluded. The primary outcomes were patient and graft survival after LT. The association between donor genotype and post-LT survival was examined using Kaplan-Meier method and multivariable-adjusted Cox proportional hazards models.
Findings UNASSIGNED
Median age of LT recipients was 57 [interquartile range (IQR), 50-62] years; 837 (35.7%) were women; 1362 (58.1%) White, 713 (30.4%) Hispanic, 182 (7.8%) Black/African-American. Median follow-up time was 3.95 years. Post-LT survival was not affected by donor
Interpretation UNASSIGNED
Donor
Funding UNASSIGNED
The National Institutes of Health and American Society of Transplant Surgeons Collaborative Scientist Grant.

Identifiants

pubmed: 38169797
doi: 10.1016/j.eclinm.2023.102350
pii: S2589-5370(23)00527-8
pmc: PMC10758751
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102350

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

All authors declare no competing interests.

Auteurs

Julia Kozlitina (J)

The Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Naomi M Cohen (NM)

The Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Division of Surgical Transplantation, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Drew Sturtevant (D)

The Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Jonathan C Cohen (JC)

The Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
The Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Cathi Murphey-Half (C)

Histocompatibility and Immunogenetics Laboratory, Southwest Immunodiagnostics, Inc, San Antonio, TX, USA.

Jerome G Saltarrelli (JG)

Histocompatibility and Immune Evaluation Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX, USA.

Peter Jindra (P)

Immune Evaluation Laboratory, Department of Surgery, Baylor College of Medicine, Houston, TX, USA.

Medhat Askar (M)

Transplant Immunology, Baylor University Medical Center, Dallas, TX, USA.

Christine S Hwang (CS)

Division of Surgical Transplantation, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Parsia A Vagefi (PA)

Division of Surgical Transplantation, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Chantale Lacelle (C)

Transplant Immunology and Histocompatibility, Department of Pathology, University of Texas Southwestern Medical Center Dallas, TX, 75390, USA.

Helen H Hobbs (HH)

The Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Malcolm P MacConmara (MP)

Division of Surgical Transplantation, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Classifications MeSH